Gotowa bibliografia na temat „Gcb-Dlbcl”
Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych
Zobacz listy aktualnych artykułów, książek, rozpraw, streszczeń i innych źródeł naukowych na temat „Gcb-Dlbcl”.
Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.
Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.
Artykuły w czasopismach na temat "Gcb-Dlbcl"
Pukiat, Sulada, Nuttapong Ngamphaiboon, Pooja Advani, Julio Chavez, George Deeb, Anjana Elefante i Francisco J. Hernandez-Ilizaliturri. "BCL-2 Expression at the Time of Diagnosis Affects the Clinical Outcome of Patients with Germinal Center and Non-Germinal Center Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Chemo-Immunotherpy". Blood 116, nr 21 (19.11.2010): 3130. http://dx.doi.org/10.1182/blood.v116.21.3130.3130.
Pełny tekst źródłaTarius, Jenifer Marsela, Hermawan Istiadi, Ika Pawitra Miranti i Intan Rahmania Eka Dini. "THE CORRELATION BETWEEN CELL OF ORIGIN SUBTYPE WITH OVERALL SURVIVAL OF DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS IN KARIADI GENERAL HOSPITAL SEMARANG". DIPONEGORO MEDICAL JOURNAL (JURNAL KEDOKTERAN DIPONEGORO) 9, nr 3 (12.05.2020): 252–58. http://dx.doi.org/10.14710/dmj.v9i3.27504.
Pełny tekst źródłaGandhi, Shipra, Vishala T. Neppalli, George Deeb, Myron S. Czuczman i Francisco J. Hernandez-Ilizaliturri. "Distinct CD30 Expression Patterns In Germinal Center B-Cell (GCB) and Non-GCB Diffuse Large B-Cell Lymphoma (DLBCL)". Blood 122, nr 21 (15.11.2013): 5064. http://dx.doi.org/10.1182/blood.v122.21.5064.5064.
Pełny tekst źródłaHayama, Miyuki, Masataka Okamoto, Yuki Hagiwara, Ken Tanae, Mika Kohri, Naoki Takahashi, Tadashi Yoshino, Koichi Ohshima i Nozomi Niitsu. "Clinical Significance of Immunohistochemical Markers of Diffuse Large B-Cell Lymphoma In the Rituximab Era." Blood 116, nr 21 (19.11.2010): 1800. http://dx.doi.org/10.1182/blood.v116.21.1800.1800.
Pełny tekst źródłaKharchenko, Yevgeniya, Tatyana Semiglazova, Anna Artemeva, Galina Kireeva, I. Polyatskin, Ilya Zyuzgin, Larisa Filatova, Yuliya Chudinovskikh, Margarita Motalkina i Yuliya Oleynik. "PROGNOSTIC IMPACT OF IMMUNOHISTOCHEMICAL AND MOLECULAR GENETIC MARKERS IN DIFFUSE LARGE B-CELL LYMPHOMA". Problems in oncology 66, nr 1 (1.01.2020): 79–89. http://dx.doi.org/10.37469/0507-3758-2020-66-1-79-89.
Pełny tekst źródłaAdhi Pangarsa, Eko, Desta Nur Ewika Ardini, Daniel Rizky, Kevin Tandarto, Hermawan Istiadi, Dik Puspasari, Budi Setiawan i in. "The association of Hypoxia-Inducible Factor-2α (HIF-2α) overexpression score with Germinal Center B-Cell Like (GCB) and Non-Germinal Center B-Cell Like (Non-GCB) subtypes of Diffuse Large B-cell Lymphoma (DLBCL)". Bali Medical Journal 12, nr 3 (22.08.2023): 2456–62. http://dx.doi.org/10.15562/bmj.v12i3.4521.
Pełny tekst źródłaMishima, Yuko, Masahiro Yokoyama, Noriko Nishimura, Kyoko Ueda, Tadahiro Gunji, Hideaki Nitta, Yoshiharu Kusano i in. "R-CHOP Therapy Cannot Overcome CD5 Positive Non-GCB Subtype of DLBCL". Blood 126, nr 23 (3.12.2015): 1507. http://dx.doi.org/10.1182/blood.v126.23.1507.1507.
Pełny tekst źródłaChavez, Julio, Mark Walsh, Francisco J. Hernandez-Ilizaliturri, Anjana Elefante i Myron S. Czuczman. "Classification of Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) According to the Han's Criteria Defines Two Groups of Patients with Different Clinical Outcomes Following Systemic Rituximab-Multi Agent Anthracycline-Based Therapy." Blood 114, nr 22 (20.11.2009): 623. http://dx.doi.org/10.1182/blood.v114.22.623.623.
Pełny tekst źródłaVan Meerten, Tom, Renee Bouwstra, Yuan He, de Boer Janneke, Hilde Kooistra, Rudolf Fehrmann, Emanuele Ammatuna, Gerwin Huls i Edwin Bremer. "CD47 Expression Defines the Efficacy of Rituximab in Non-Germinal Center B-Cell (non-GCB) Diffuse Large B-Cell Lymphoma (DLBCL)". Blood 132, Supplement 1 (29.11.2018): 2852. http://dx.doi.org/10.1182/blood-2018-99-114561.
Pełny tekst źródłaNiitsu, Nozomi, Naoki Takahashi, Tadashi Yoshino, Masataka Okamoto i Shigeo Nakamura. "Prognostic Significance of EBV Association in Diffuse Large B-Cell Lymphoma in the Rituximab Era". Blood 126, nr 23 (3.12.2015): 3911. http://dx.doi.org/10.1182/blood.v126.23.3911.3911.
Pełny tekst źródłaRozprawy doktorskie na temat "Gcb-Dlbcl"
Prévaud, Léa. "Rôle de la sous-unité c-Rel NFkB dans les Lymphômes B Diffus à Grandes Cellules du Centre Germinatif (GCB-DLBCLs) : établissement d'un modèle murin préclinique". Electronic Thesis or Diss., Limoges, 2023. http://www.theses.fr/2023LIMO0108.
Pełny tekst źródłaThe transcription factor Rel/NF-kB includes 5 subunits (SU), p50, p52, c-Rel, RelA and RelB which associate into dimers. NF-κB is at the heart of the ontogeny of mature B lymphocytes in the germinal centers (GC) for c-Rel and RelB and during plasma cell differentiation for RelA. Diffuse large cell lymphoma (DLBCL) represent more than 80% of aggressive B-cell lymphomas. We have published that NF-kB SUs must be taken into account differentially, such that RelB is a marker of poor prognosis, RelA is the SU of the ABC molecular subtype (activated B cell) and cRel that of GCB (germinal center B cell)-DLBCL with a novel clean transcriptomic signature. This project consists of understanding mechanistically how c-Rel induces the transformation of a GC B lymphocyte. We have established a new mouse model of c-Rel overexpression (with YFP) in some CG B lymphocytes (tdTomato-AID-Creert2) and are testing the clonal emergence of a tumor. The originality of this inducible model relies in the fact that it makes it possible to follow the competition between the B of the GCs on expressed c-Rel (tdTomato and YFP) compared to their normal counterpart (tdTomato)
Wu, Yen-Fei, i 吳彥霏. "The Role of Galectin-9 in Germinal Centre B-cell-like Diffuse Large B Cell Lymphoma (GCB-DLBCL)". Thesis, 2016. http://ndltd.ncl.edu.tw/handle/72125881113790583302.
Pełny tekst źródła國立臺灣大學
免疫學研究所
104
Galectin-9, a tandem-repeat type galectin, was first identified in patients with a nodular sclerosis type of Hodgkin’s disease. Previous studies demonstrated various regulatory roles of galectin-9 in the immune responses. However, role of galectin-9 in cancer biology remains elusive. Here, we found galectin-9 expression in germinal centre B-cell-like diffuse large B cell lymphoma (GCB DLBCLs) was up-regulated amongst germinal center lymphomas. To determine the role of elevated galectin-9 expression in vivo, we used NOD/SCID xenograft model of GCB DLBCLs. Strikingly, we observed a dramatic reduction of tumor volume and weight in mice receiving galectin-9 knockdown GCB DLBCL cells. Interestingly, knockdown of galectin-9 did not affect the tumorigenicity in NOD scid gamma (NSG) xenograft model, which implied natural killer (NK) cells might be responsible for the reduced tumor size in NOD/SCID mice. Thus, depletion of NK cells was achieved by anti-asGM1 antibody in NOD/SCID mice. As a result, we found partially restored tumorigenicity in NOD/SCID mice engrafted with galectin-9 knockdown GCB DLBCLs after NK cell depletion. Moreover, tumor-infiltrating NK cells were significantly increased in galectin-9-depleted tumors in NOD/SCID mice. In term of molecular mechanisms, knockdown of galectin-9 induces neither apoptosis nor cell cycle arrest in GCB DLBCLs. On the other hand, we found that the level of c-Jun, a regulator in tumor microenvironment, was decreased in galectin-9 knockdown GCB DLBCL tumors. These data suggested that galectin-9 derived from GCB-DLBCL might cause the immune escape through inhibiting NK cell activity.
Części książek na temat "Gcb-Dlbcl"
Abraham Jacob, Linu, i Animesh Gupta. "DLBCL Subtypes and Prognosis Based on Immunophenotyping". W Lymphoma - Recent Advances [Working Title]. IntechOpen, 2023. http://dx.doi.org/10.5772/intechopen.109216.
Pełny tekst źródłaStreszczenia konferencji na temat "Gcb-Dlbcl"
Koning, Marvyn T., Rudolf Übelhart, Arjen H. G. Cleven, Willem H. Zoutman, Sander A. J. van der Zeeuw, Philip Kluin, Marieke Griffioen i in. "Abstract LB-012: Autonomous, antigen-independent B-cell receptor signalling as a novel pathogenetic mechanism in non-GCB DLBCL". W Proceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1538-7445.am2016-lb-012.
Pełny tekst źródłaMaerevoet, Marie, Jason Westin, Catherine Thieblemont, Josee Zijlstra, Brian T. Hill, Fatima De La Cruz Vicente, Sylvain Choquet i in. "Abstract CT132: A Phase 2b randomized study of selinexor in patients with relapsed/refractory Diffuse Large B-Cell Lymphoma (DLBCL) demonstrates durable responses in both GCB & Non-GCB subtypes". W Proceedings: AACR Annual Meeting 2017; April 1-5, 2017; Washington, DC. American Association for Cancer Research, 2017. http://dx.doi.org/10.1158/1538-7445.am2017-ct132.
Pełny tekst źródłaLin, Xiaoyu, Xiaoli Huang, Aparna Sarthy, Terry Magoc, Daniel Albert, Lloyd Lam, Tamar Uziel i in. "Abstract 4706: ABBV-075 exhibits robust in vitro and in vivo activities against the ABC and GCB subtypes of DLBCL". W Proceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1538-7445.am2016-4706.
Pełny tekst źródłaKawagishi, Aki, Hiroki Irie, Yoshio Ogino, Hideya Komatani i Teruhiro Utsugi. "Abstract A274: Novel SYK inhibitors have demonstrated potent antiproliferative effects in both ABC- and GCB-DLBCL cell lines via suppression of multiple pathways downstream of the B-cell receptor." W Abstracts: AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics--Oct 19-23, 2013; Boston, MA. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1535-7163.targ-13-a274.
Pełny tekst źródła